Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacubitril-valsartan versus ACE inhibitor versus angiotensin receptor blocker in heart failure
IRCT20120215009014N503Phase 3Completed
- Sponsor
- Hamadan University of Medical Sciences
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sacubitril + valsartan in heart failure (HF) (3 arms), sponsored by Hamadan University of Medical Sciences. Primary endpoints: Average blood pressure, Mean serum creatinine and 5 more. Started Apr 2024; status: completed.
02
Drugs
sacubitril + valsartan
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on IRCT20120215009014N503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20120215009014N503.